Package Leaflet: Information for the Patient
Teriflunomide Dr. Reddys 7 mg film-coated tablets EFG
Teriflunomide Dr. Reddys 14 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
What is Teriflunomide Dr. Reddys
This medication contains the active substance teriflunomide, which is an immunomodulatory agent that adjusts the immune system to limit its attack on the nervous system.
What is Teriflunomide Dr. Reddys used for
Teriflunomide is used in adults and in children and adolescents (10 years of age and older) to treat relapsing-remitting multiple sclerosis (MS).
What is multiple sclerosis
MS is a long-term disease that affects the central nervous system (CNS). The CNS is made up of the brain and spinal cord. In multiple sclerosis, inflammation destroys the protective sheath (myelin) that surrounds the nerves of the CNS. This loss of myelin is called demyelination. This causes the nerves to stop functioning properly.
People with the relapsing form of multiple sclerosis will have repeated attacks (relapses) of physical symptoms caused by the malfunctioning of the nerves. These symptoms vary from person to person but usually include:
The symptoms may disappear completely after a relapse, but over time, some problems may persist. This can cause physical disabilities that can interfere with daily activities.
How Teriflunomide Dr. Reddys works
Teriflunomide helps protect against attacks on the central nervous system by the immune system, limiting the growth of certain white blood cells (lymphocytes). This limits the inflammation that causes nerve damage in MS.
Do not take Teriflunomide Dr. Reddys:
In case of doubt, ask your doctor or pharmacist before taking this medication.
Consult your doctor or pharmacist before starting to take Teriflunomide Dr. Reddys if:
Tell your doctor if you have unexplained cough and shortness of breath. Your doctor may perform additional tests.
Teriflunomide is not indicated for use in children under 10 years of age, as it has not been studied in patients with MS in this age group.
The warnings and precautions listed above also apply to children. The following information is important for children and their caregivers:
In particular, tell your doctor or pharmacist if you are taking any of the following medications:
Do nottake teriflunomide if you are pregnant or think you may be pregnant. If you are pregnant or become pregnant while taking teriflunomide, you will increase the risk of having a baby with birth defects.
Women of childbearing age should not take this medication if they are not using reliable contraceptive methods.
If your daughter has her first menstrual period while taking teriflunomide, she should inform her doctor, who will provide specialized advice on contraceptive methods and potential risks in case of pregnancy.
Tell your doctor if you plan to become pregnant after stopping treatment with teriflunomide, as you will need to make sure that most of this medication has been eliminated from your body before trying to become pregnant. The elimination of the active substance naturally may take up to 2 years. This period can be reduced to a few weeks by taking certain medications to accelerate the elimination of teriflunomide from the body.
In any case, you need your doctor to confirm, based on a blood test, that the level of the active substance in your blood is low enough for you to become pregnant.
For more information on laboratory tests, contact your doctor.
If you suspect you are pregnant while taking teriflunomide or in the two years following the end of treatment, you should stop taking teriflunomide and contact your doctor immediatelyto have a pregnancy test. If the test confirms pregnancy, your doctor may suggest treatment with certain medications to eliminate teriflunomide from your body quickly enough, as this may reduce the risk to your baby.
Contraception
You should use an effective contraceptive method during and after treatment with teriflunomide. Teriflunomide remains in the blood for a long time after stopping it. Continue to take contraceptive measures after stopping treatment.
Do not take teriflunomide during breastfeeding, as teriflunomide passes into breast milk.
Teriflunomide may cause dizziness, which may affect your ability to concentrate and react. If you are affected, do not drive or use machines.
Teriflunomide contains lactose (a type of sugar). If your doctor has told you that you have an intolerance to certain sugars, consult them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".
A doctor with experience in treating multiple sclerosis will supervise treatment with teriflunomide.
Follow the instructions for administration of this medication exactly as indicated by your doctor. In case of doubt, consult your doctor again.
The recommended dose is one 14 mg tablet per day.
The dose depends on body weight:
Your doctor will instruct children and adolescents who reach a stable body weight over 40 kg to switch to a 14 mg tablet per day.
Form/Route of Administration
Teriflunomide is administered orally.
Teriflunomide is taken once daily, in a single daily dose, at any time of day.
The tablet should be swallowed whole with water.
Teriflunomide can be taken with or without food.
If you have taken too much teriflunomide, call your doctor immediately. You may experience side effects similar to those described in section 4 below.
In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
Do not take a double dose to make up for forgotten doses. Take your next dose at the scheduled time.
Do not stop treatment or change the dose of teriflunomide without consulting your doctor first. If you have any further questions on the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone gets them.
The following side effects can occur with this medication.
Some side effects can be serious, and if you experience any of them, tell your doctor immediately.
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Frequency Not Known(frequency cannot be estimated from the available data)
Other Side Effectsmay occur with the following frequencies:
Very Common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 patients)
Frequency Not Known(frequency cannot be estimated from the available data)
The side effects listed above also apply to children and adolescents. The following additional information is important for children, adolescents, and their caregivers:
Common(may affect up to 1 in 10 people)
Reporting Side Effects
If you experience any side effects, consult your doctor or pharmacist, even if they are side effects not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, and the blister after "EXP". The expiry date refers to the last day of the month indicated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the SIGRE collection point at your pharmacy. If you are unsure, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Teriflunomida Dr. Reddys
The active ingredient is teriflunomide.
Teriflunomida Dr. Reddys 7 mg film-coated tablets
Each tablet contains 7 mg of teriflunomide.
The other ingredients are lactose monohydrate, microcrystalline cellulose, maize starch, sodium carboxymethylcellulose (Type A) potato, hydroxypropylcellulose, magnesium stearate, hypromellose, calcium carbonate, triacetin.
Teriflunomida Dr. Reddys 14 mg film-coated tablets
Each tablet contains 14 mg of teriflunomide.
The other ingredients are lactose monohydrate, microcrystalline cellulose, maize starch, sodium carboxymethylcellulose (Type A) potato, hydroxypropylcellulose, magnesium stearate, hypromellose, calcium carbonate, triacetin, aluminium lake indigo carmine (E132).
Appearance and Package Contents
Teriflunomida Dr. Reddys 7 mg film-coated tablets
The 7 mg film-coated tablets are round, white, 6 mm in diameter, and marked with an "O" on one face.
Package sizes: 28, 28x1, or 84 film-coated tablets
Teriflunomida Dr. Reddys 14 mg film-coated tablets
The 14 mg film-coated tablets are round, blue, 7 mm in diameter, and marked with "C14" on one face.
Package sizes: 28, 28x1, 56, 84, or 98 film-coated tablets
Not all package sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Reddy Pharma Iberia, S.A.
Avda. Josep Tarradellas nº 38
08029 Barcelona (Spain)
Telephone: 93.355.49.16
Fax: 93.355.49.61
Manufacturer
Coripharma ehf.
Reykjavikurvegur 78
IS-220 Hafnarfjordur
Iceland
This medicine is authorised in the Member States of the European Economic Area under the following names:
Country | Name |
Germany | Teriflunomid beta 7 mg Filmtabletten Teriflunomid beta 14 mg Filmtabletten |
Spain | Teriflunomida Dr. Reddys 7 mg comprimidos recubiertos con película EFG Teriflunomida Dr. Reddys 14 mg comprimidos recubiertos con película EFG |
Italy | Teriflunomide Dr. Reddy’s |
Romania | Teriflunomida Dr. Reddy’s 14 mg comprimate filmate |
Date of last revision of this leaflet:April 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.